Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obervation Letter
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF
Letter to the Editor - Study Letter
2019:85:2;195-196
doi: 10.4103/ijdvl.IJDVL_252_18
PMID: 30719989

Serum galectin-9 levels in atopic dermatitis, psoriasis and allergic contact dermatitis: A cross-sectional study

Eman Nofal1 , Fatma Eldesoky1 , Ahmad Nofal1 , Ahmed Abdelshafy1 , Amal Zedan2
1 Department of Dermatology and Venereology, Faculty of Medicine, Zagazig University, Zagazig, Egypt
2 Department of Clinical Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

Correspondence Address:
Eman Nofal
Department of Dermatology and Venereology, Faculty of Medicine, Zagazig University, Zagazig
Egypt
Published: 31-Jan-2019
How to cite this article:
Nofal E, Eldesoky F, Nofal A, Abdelshafy A, Zedan A. Serum galectin-9 levels in atopic dermatitis, psoriasis and allergic contact dermatitis: A cross-sectional study. Indian J Dermatol Venereol Leprol 2019;85:195-196
Copyright: (C)2019 Indian Journal of Dermatology, Venereology, and Leprology

Sir,

Galectin-9 (Gal-9) is a tandem-repeat galectin that is widely distributed in human tissues, including epithelial tissues. Galectin-9 is a physiological ligand for T-cell-immunoglobulin- and mucin-domain-containing molecule-3 (TIM-3) that is specifically expressed in T helper 1 cells (Th1) and T helper 17 cells (Th17), but not in T helper 2 cells (Th2). The interaction of TIM-3 and Gal-9 induces apoptosis in Th1 and Th17 cells.[1] Dysregulation of Gal-9-TIM-3 network probably causes several allergic or autoimmune diseases.[2] Atopic dermatitis, psoriasis and allergic contact dermatitis are common inflammatory skin diseases associated with immunological abnormalities. Atopic dermatitis is characterized by Th2 cell predominance, which is proposed to play a key pathogenetic role in atopic dermatitis, while psoriasis and allergic contact dermatitis are generally thought to be mediated by Th1 and Th17 cells. The aim of this work was to investigate a potential role of Gal-9 in the pathogenesis of atopic dermatitis, psoriasis and allergic contact dermatitis and to assess its relation to disease severity.

A total of 54 patients (18 atopic dermatitis, 18 psoriasis, 18 allergic contact dermatitis) with different grades of disease severity and 18 healthy subjects were recruited at the outpatient clinics of dermatology and venereology department, Zagazig University Hospitals. The severity of the diseases was determined by SCORAD in atopic dermatitis cases, by PASI score in psoriasis cases and by staging of allergic contact dermatitis. Serum Gal-9 levels were measured in all patients and controls by enzyme-linked immunosorbent assay. The mean serum levels of Gal-9 were 291.89 ± 67.66 pg/ml in control group, 1199 ± 697.65 pg/ml in atopic dermatitis group, 332.98 ± 61.3 pg/ml in psoriasis and 325.6 ± 64.67 pg/ml in allergic contact dermatitis group [Figure - 1]. A highly significant elevation in serum levels of Gal-9 in atopic dermatitis patients was detected (P = 0.001) and was positively correlated with the disease severity (P = 0.03). The more the severity of atopic dermatitis, the higher the serum levels of Gal-9 [Figure - 2]. No statistical differences were detected between the serum levels of Gal-9 in psoriasis and allergic contact dermatitis groups and the control group (P = 0.07 and 0.12, respectively). Moreover, there were no significant associations between the severity of psoriasis or allergic contact dermatitis and serum levels of Gal-9 (P = 0.15 and 0.49, respectively).

Figure 1: Mean serum galectin-9 levels among the three studied groups and controls
Figure 2: Positive correlation between the severity of atopic dermatitis and serum galectin-9 levels

As far as we know, the study of Nakajima et al. is the only study that investigated serum Gal-9 in atopic dermatitis and reported elevated serum Gal-9 levels in patients than controls and showed stronger expression of Gal-9 on epidermal keratinocytes and mast cells in atopic dermatitis skin than in normal skin.[3] They also found a significant decrease in the serum levels of Gal-9 with improvement of the skin lesions of atopic dermatitis after treatment. Several mechanisms have been suggested to explain the role of Gal-9 in atopic dermatitis. Gal-9 induces apoptosis in Th1 and Th17 cells through binding with its ligand TIM-3 resulting in Th2 polarization. The Th2 polarized microenvironment in lesional skin of atopic dermatitis induces Gal-9 upregulation with subsequent exacerbation of Th2 polarization. Dendritic cellsplay a crucial role in Th2 skewing, and mediate the development of atopic dermatitis. The role of Gal-9 in dendritic cell maturation has been assessed. The role of eosinophils in the pathogenesis of atopic dermatitis has been suggested. Gal-9 has an eosinophil attractant effect. Increased levels of Gal-9 in atopic dermatitis may have a role in eosinophilia detected in atopic patients. Increased mast cell numbers and activation were reported in chronic skin lesions of atopic dermatitis. The role of mast cells in the pathogenesis of atopic dermatitis is controversial. Gal-9 has a dual role in the function of mast cells.

In the psoriatic group, our results supported those of de la Fuente et al. who reported that the expression of Gal-9 in psoriatic skin and control skin was the same. However, they did not measure its levels in serum. We could not find previous studies investigating Gal-9 expression (either in serum or tissue) in allergic contact dermatitis. Downregulation of Gal-9 level was expected in cases of psoriasis and allergic contact dermatitis which could promote the Th1 and Th17 immune response observed in psoriasis and allergic contact dermatitis. Although this study may suggest that Gal-9 has no role in the pathogenesis of either disease, the study of Niwa et al. reported marked therapeutic effect in induced psoriasis and allergic contact dermatitis in mouse models by administration of stable Gal-9 and suggested Gal-9 as a unique and useful therapeutic tool for the treatment of Th1 and/or Th17 mediated skin disorders.[5] In conclusion, Gal-9 may be implicated in the pathogenesis of atopic dermatitis and is correlated to disease severity. Its role in psoriasis and allergic contact dermatitis could not be verified by this study. Restoration of the immune equilibrium lost in atopic dermatitis, psoriasis and allergic contact dermatitis by galectins require increased recognition of these molecules as immunoregulatory molecules and as a new therapeutic tool.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patients have given their consent for their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References
1.
Kashio Y, Nakamura K, Abedin MJ, Seki M, Nishi N, Yoshida N, et al. Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. J Immunol 2003;170:3631-6.
[Google Scholar]
2.
Anderson AC, Anderson DE. TIM-3 in autoimmunity. CurrOpin Immunol 2006;18:665-9.
[Google Scholar]
3.
Nakajima R, Miyagaki T, Oka T, Nakao M, Kawaguchi M, Suga H, et al. Elevated serum galectin-9 levels in patients with atopic dermatitis. J Dermatol 2015;42:723-6.
[Google Scholar]
4.
de la Fuente H, Perez-Gala S, Bonay P, Cruz-Adalia A, Cibrian D, Sanchez-Cuellar S, et al. Psoriasis in humans is associated with down-regulation of galectins in dendritic cells. J Pathol2012;228:193-203.
[Google Scholar]
5.
Niwa H, Satoh T, Matsushima Y, Hosoya K, Saeki K, Niki T, et al. Stable form of galectin-9, a Tim-3 ligand, inhibits contact hypersensitivity and psoriatic reactions: A potent therapeutic tool for Th1 – and/or Th17-mediated skin inflammation. Clin Immunol 2009;132:184-94.
[Google Scholar]

Fulltext Views
202

PDF downloads
83
Show Sections